Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC) (original) (raw)

Journal of Clinical Oncology, 2018

Abstract

4110Background: NAPA is an oral investigational agent, hypothesized to inhibit cancer stemness pathways, including STAT3 pathway implicated in cancer stem-cell viability. We report updated data in ...

Xiaoshu Dai hasn't uploaded this paper.

Let Xiaoshu know you want this paper to be uploaded.

Ask for this paper to be uploaded.